271 related articles for article (PubMed ID: 28771663)
41. Nelarabine.
Sanford M; Lyseng-Williamson KA
Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
[TBL] [Abstract][Full Text] [Related]
42. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
[TBL] [Abstract][Full Text] [Related]
43. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
[TBL] [Abstract][Full Text] [Related]
44. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
45. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Hartz B; Löbel U; Hagel C; Escherich G
Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
[No Abstract] [Full Text] [Related]
46. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
Kadia TM; Gandhi V
Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
[TBL] [Abstract][Full Text] [Related]
47. Update on biology and treatment of T-cell acute lymphoblastic leukaemia.
Patrick K; Vora A
Curr Opin Pediatr; 2015 Feb; 27(1):44-9. PubMed ID: 25502893
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
50. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
[TBL] [Abstract][Full Text] [Related]
51. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Curbo S; Karlsson A
Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
[TBL] [Abstract][Full Text] [Related]
52. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
53. Nelarabine: efficacy in the treatment of clinical malignancies.
Roecker AM; Allison JC; Kisor DF
Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
[TBL] [Abstract][Full Text] [Related]
56. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
[No Abstract] [Full Text] [Related]
57. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
58. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
Uyttebroeck A; Suciu S; Laureys G; Robert A; Pacquement H; Ferster A; Marguerite G; Mazingue F; Renard M; Lutz P; Rialland X; Mechinaud F; Cavé H; Baila L; Bertrand Y;
Eur J Cancer; 2008 Apr; 44(6):840-6. PubMed ID: 18342502
[TBL] [Abstract][Full Text] [Related]
59. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
60. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
